Clinical Trial

Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate the effects of donanemab (LY3002813) versus placebo in Chinese participants who are at risk for decline of memory, language and physical ability to perform activities of daily living from Alzheimer's disease (AD). The study drug will be administered intravenously (IV) (into a vein in the arm). The study will last up to approximately 156 weeks, excluding screening.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-27
Trial Details
NCT Number NCT07571161
Lead Sponsor Eli Lilly and Company
Conditions Alzheimer Disease
Enrollment 140 participants
Start Date 2026-04-30
Primary Completion 2030-04 (estimated)
Study Completion 2030-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-06